8.05
Elicio Therapeutics Inc stock is traded at $8.05, with a volume of 288.71K.
It is up +1.13% in the last 24 hours and up +46.36% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$7.96
Open:
$8.05
24h Volume:
288.71K
Relative Volume:
6.87
Market Cap:
$128.30M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3146
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+5.92%
1M Performance:
+46.36%
6M Performance:
+64.96%
1Y Performance:
+21.60%
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ELTX
Elicio Therapeutics Inc
|
8.05 | 128.30M | 0 | -33.82M | -66.04M | -25.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Elicio Therapeutics Secures Strategic Financing As Pivotal Cancer Trial Data Approaches - Barchart.com
Elicio Therapeutics to Host Virtual KOL Event on June 25, - GlobeNewswire
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewswire Inc.
Elicio secures $10 million to extend cash runway By Investing.com - Investing.com South Africa
Elicio Therapeutics Secures $10 Million in Financing - citybiz
Elicio Therapeutics Gets $10 Million Note Financing - marketscreener.com
Elicio secures $10 million to extend cash runway - Investing.com
Elicio Therapeutics Secures $10M Financing for Operations - TipRanks
Elicio Therapeutics (ELTX) Secures $10M Financing to Extend Operations | ELTX Stock News - GuruFocus
Elicio Therapeutics Lands $10M Funding to Advance Revolutionary Cancer Vaccine Through Critical Trial Phase - Stock Titan
When the Price of (ELTX) Talks, People Listen - news.stocktradersdaily.com
Elicio Therapeutics announces board election results By Investing.com - Investing.com Nigeria
Elicio Therapeutics Elects New Directors at Annual Meeting - TipRanks
Elicio Therapeutics announces board election results - Investing.com
Elicio Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Elicio's (ELTX) ELI-002 Interim Analysis Anticipated in Phase 2 Trial | ELTX Stock News - GuruFocus
Elicio Therapeutics: Q1 Earnings Snapshot - CTPost
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Learn to Evaluate (ELTX) using the Charts - news.stocktradersdaily.com
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Long Term Trading Analysis for (ELTX) - news.stocktradersdaily.com
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewswire
Key Executive Appointment: Elicio Therapeutics Names New Chief Strategy and Financial Officer - Stock Titan
Elicio Therapeutics grants inducement award to new chief strategy and financial officer - MSN
(ELTX) Investment Report - news.stocktradersdaily.com
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Earnings Preview: What To Expect From Johnson & Johnson's Report - Barchart.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView
Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elicio Therapeutics, Inc. SEC 10-K Report - TradingView
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks
Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):